# Sermorelin Body Composition Research: Fat, Lean Mass, and the Evidence > Sermorelin Body Composition Research: what GH/IGF-1 physiology and GHRH-analog trials show about fat and lean mass — and where sermorelin-specific adult data stop. Where the fat and lean-mass evidence actually comes from — GH/IGF-1 physiology and the related analog tesamorelin — and the honest terminus where sermorelin-specific adult data stop. ## The short version Sermorelin Body Composition Research is mostly a story about the company it keeps. Sermorelin itself raises GH and IGF-1 — the hormones tied to how the body handles fat and muscle — but controlled fat-loss or muscle-gain outcomes in healthy adults taking sermorelin specifically are not established. The strongest body-composition numbers come from two neighbors: the physiology of pulsatile GH and lipolysis (fat breakdown), and trials of tesamorelin, a stabilized GHRH analog in the same drug class. This page keeps that line clearly drawn — what is sermorelin's, what is the class's, and where the evidence ends. "Lipolysis" just means the body releasing stored fat; "visceral fat" is the fat packed around the organs. ## What the GH/IGF-1 axis does to fat Pulsatile growth-hormone secretion helps regulate lipolysis — the release of stored fat — in fasting humans, which is why preserving the natural, bursty GH pattern (the pattern GHRH stimulation supports) is metabolically relevant [7]. Sermorelin's appeal in this space rests on that physiology: by prompting the pituitary's own pulses, it engages the same axis the body uses to mobilize fat. A GHRH analog has been shown to alter endogenous GH pulsatility and insulin sensitivity in healthy men, confirming that GHRH-axis stimulation reaches glucose and fat handling, not just GH levels [8]. These are mechanism findings — they explain why the axis matters, not that sermorelin produces a given amount of fat loss. The axis also runs both ways, which complicates the simple story. In a controlled clamp study, abdominal visceral fat was the single dominant negative determinant of GHRH-stimulated GH release, accounting for about 41% of the variance, while IGF-1 positively predicted the GH response [10]. In plain terms: the more visceral fat a person carries, the blunter their GH response to a GHRH signal tends to be — so the population most often targeted for "fat loss" may be the population in which the secretagogue response is most damped. That is a reason to read body-composition claims cautiously, not a reason to assume a guaranteed effect. ## Sermorelin vs Tesamorelin Much of the credible body-composition evidence in this drug class belongs to tesamorelin, a stabilized synthetic GHRH analog, not to sermorelin. A review of tesamorelin documents its pharmacology and clinical use in HIV-associated lipodystrophy, the condition for which that analog was developed [11]. In a 20-week randomized, placebo-controlled trial of a GHRH analog in 152 older adults, percent body fat fell by 7.4% while IGF-1 rose 117% within the physiologic range [6]. The honest framing: these are tesamorelin/GHRH-analog results. They are class-relevant context for sermorelin — same receptor, same axis — but they are not sermorelin-specific outcomes, and this page flags them as such rather than borrowing them. ## Sermorelin and Weight Loss in Studies **Sermorelin weight loss** has no controlled trial behind it in healthy adults. The 16-week analog study in older men and women explicitly found no change in body weight, with rising IGF-1 and IGFBP-3 [9]. The body-composition signals that do exist trace to GH/IGF-1 physiology [7] and to the related analog tesamorelin [6][11], not to demonstrated sermorelin-driven weight loss. A clamp study adds a determinant worth noting: abdominal visceral fat was the dominant negative predictor of GHRH-stimulated GH release (41% of the variance), so higher visceral fat blunts the very GH response the peptide aims to provoke [10]. ## What Studies Report Before and After Sermorelin The credible **sermorelin before and after** picture is measured, not cosmetic. In GH-deficient children, GHRH(1-29) raised first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]. In older men, 14 days of twice-daily GHRH(1-29) restored GH and IGF-1 toward young-adult levels [2]. Over 16 weeks, an analog raised IGF-1 and IGFBP-3 without changing body weight [9]. Adult cosmetic before/after claims — visible fat loss, dramatic recomposition — outpace this controlled evidence, which is exactly the gap the literature flags. ## Does sermorelin burn fat? Research on GHRH-axis stimulation links pulsatile GH to lipolysis [7], and the stabilized analog tesamorelin significantly reduced visceral fat versus placebo in clinical trials [11]. Sermorelin-specific fat-loss outcomes in healthy adults, however, are not established — the fat-burning case is built from axis physiology and a related analog, not from sermorelin trials [9]. ## Is sermorelin effective for weight loss? No controlled trial shows sermorelin produces weight loss in healthy adults; the 16-week analog study found no body-weight change [9]. The body-composition evidence comes largely from the related analog tesamorelin in specific clinical populations [6][11] and from GH/IGF-1 physiology [7], not from sermorelin itself. ## Does sermorelin build muscle? Sermorelin raises GH and IGF-1, the axis associated with lean-mass regulation [2], and reviews discuss GH/IGF-1 modulation in the context of age-related decline [12]. Direct muscle-building outcomes for sermorelin in healthy adults are not demonstrated; the lean-mass link is mechanistic, drawn from the hormones it elevates rather than from a sermorelin muscle trial. ## Sermorelin before and after: what changes do studies report? In GH-deficient children, GHRH(1-29) raised first-year height velocity from about 4.1 to roughly 7-8 cm/year [1]; in older men, 14 days of twice-daily GHRH(1-29) restored GH and IGF-1 toward young-adult levels [2]. Adult cosmetic before/after claims outpace the controlled evidence, and the analog studies that report body-fat change are tesamorelin, not sermorelin [6][9]. --- A transit-board reading of the sermorelin literature — the GHRH(1-29) findings routed line by line, each GH and IGF-1 figure carried back to its study, the body-composition evidence marked as tesamorelin where it belongs, and the stop where the long-term adult data run out left openly unserviced; no clinic at this board and nothing here dosed, dispensed, or sold.